Related Experiment Video
Updated: May 2, 2026
Field-Deployable Candidatus Liberibacter asiaticus Detection Using Recombinase Polymerase Amplification Combined with CRISPR-Cas12a
Published on: December 23, 2022
SlipChip Enables the Integration of CRISPR-Cas12a and RPA for Fast and Stand-Alone HPV Detection
Yin Zhao1,2, Zheyu Li3,4, Tao Li1,3,4
1State Key Laboratory of Magnetic Resonance and Atomic Molecular Physics, Wuhan National Laboratory for Optoelectronics, National Centre for Magnetic Resonance in Wuhan, Wuhan Institute of Physics and Mathematics, Innovation Academy for Precision Measurement Science and Technology - Wuhan National Laboratory for Optoelectronics, Chinese Academy of Sciences, Wuhan 430071, China.
A new portable nucleic acid testing platform, SMART, rapidly detects HPV16 and HPV18 in 36 minutes. This advancement offers sensitive and specific cervical cancer screening, especially for resource-limited settings.
Area of Science:
- Biotechnology
- Molecular Diagnostics
- Public Health
Background:
- Cervical cancer screening relies on Human Papillomavirus (HPV) detection.
- Current HPV testing methods often lack speed, simplicity, and multiplexing capabilities.
- Resource-limited settings face significant challenges in implementing advanced HPV diagnostics.
Purpose of the Study:
- To develop a portable, multiplexed, and rapid nucleic acid testing platform for simultaneous HPV16 and HPV18 detection.
- To create a stand-alone system integrating RPA and Cas12a assays on a SlipChip.
- To enhance HPV screening accessibility, particularly in underserved areas.
Main Methods:
- Development of the SMART (SlipChip-based Multiplexed And Rapid Nucleic acid Testing) platform.
- Integration of Recombinase Polymerase Amplification (RPA) and Cas12a assays on a SlipChip.
- Inclusion of a heating membrane for on-chip temperature control and an All-in-One imaging mode for data acquisition.
Main Results:
- SMART achieved simultaneous detection of HPV16 and HPV18 DNA in 36 minutes.
- The platform demonstrated a low detection limit of approximately 6 copies per reaction.
- Clinical validation with 56 samples showed 97.7% sensitivity and 100% specificity for HPV detection.
Conclusions:
- SMART provides a stand-alone, rapid, and multiplexed solution for distinguishing between high-risk HPV subtypes.
- The platform shows significant potential for improving cervical cancer early detection globally.
- This technology can advance nucleic acid testing applications in diverse settings.
